Efficacy of YKP3089 in Patients With Photosensitive Epilepsy

Phase 2 Completed 11 enrolled SK Life Science, Inc. The Epilepsy Study Consortium · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

The aim of this study is to evaluate the ability of a single oral dose of YKP3089 to abolish or clearly reduce the IPS-induced photo-paroxysmal EEG response in photosensitive epilepsy patients, and to measure the onset and duration of the effect. Several cohorts will be used, to sequentially investigate different doses.

Timeline

Start: 2007-08
Primary completion: 2009-01
Completion: 2010-01

Publications

Kasteleijn-Nolst Trenite DGA, DiVentura BD, Pollard JR, Krauss GL, Mizne S, French JA. Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089). Neurology. 2019 Aug 6;93(6):e559-e567. doi: 10.1212/WNL.0000000000007894. Epub 2019 Jul 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cenobamate	Small molecule	100 mg	Oral
Subject	Cenobamate	Small molecule	250 mg	Oral
Subject	Cenobamate	Small molecule	400 mg	Oral

Efficacy of YKP3089 in Patients With Photosensitive Epilepsy

Summary

Timeline

Publications

Drugs

Indications